Simpson Thacher recently represented the initial purchasers in connection with an offering of Notes by Roche Holdings, Inc. (“Roche”). The offering consisted of a Rule 144A and Regulation S offering of $1.1 billion of 5.265% notes due 2026, $1.25 billion of 5.338% notes due 2028, $1.25 billion of 5.489% notes due 2030, $1.6 billion of 5.593% notes due 2033 and $300 million of floating rate notes due 2026 (together, the “Notes”).~~The net proceeds from the issue of the Notes will be used for general corporate purposes, including, among others, to fund a portion of the cash consideration payable in connection with the acquisition of Telavant Holdings, Inc. The Roche Group is the world’s leading supplier of in vitro diagnostics, one of the world’s largest biotech companies and a leading provider of cancer treatment drugs worldwide.~~The Simpson Thacher team included Mark Brod, Alexander Yeagley and Julia Szinovatz (Capital Markets); Michael R. Isby, Vanessa Burrows and Nawa Lodin (Corporate); Bobbie Burrows and Cara Anstey (IP); and Jonathan Cantor and Lina Pan (Tax).